Topical SGX302 for Mild-to-Moderate Psoriasis
Phase 2 Study Evaluating SGX302 (Synthetic Hypericin) in the Treatment of Mild-to-Moderate Psoriasis
To evaluate SGX302 (topical hypericin ointment and gel) with visible light in an initial 18-week treatment course for improving lesions in patients with mild-to-moderate psoriasis.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
California
-
San Diego, California, United States, 92123
- Therapeutics Clinical Research
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Have a clinical diagnosis of plaque psoriasis (psoriasis vulgaris) of at least 6-months duration that involves the body (trunk and/or limbs) that is amenable to topical treatment and opaque coverage after application.
- Have a static Investigator Global Assessment (IGA)/Psoriasis Area and Severity Index (PASI) of disease severity of mild or moderate on the body (trunk and/or limbs).
- Have lesions involving 2-30% of the body (trunk and/or limbs). For subjects with scalp psoriasis included in the treatment area, the total treatment area on body and scalp must not exceed 30%.
Exclusion Criteria:
- Use of topical anti psoriatic therapy within one week prior to the beginning of the study and willing to not use other psoriasis treatments for 4 weeks following completion of the treatment portion of the study.
- Received systemic biologic therapy to treat psoriasis within 12 weeks prior to the beginning of the study.
- Received systemic psoriasis therapy within 4 weeks prior to the beginning of the study.
- Received phototherapy (including laser) or photodynamic (light activated drug) therapy within 4 weeks prior to the beginning of the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Sequential Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Cohort 1 - SGX302 Ointment (0.25 % Hypericin)
SGX302 (0.25 % hypericin) ointment will be applied to lesions and treated with visible light 24±6 hours later starting at 5 J/cm^2 with a gradual escalation of light therapy up to 25 J/cm^2. Drug application/light session will be done twice a week (at least 2 calendar days apart) for 18 weeks. |
SGX302 is synthetic hypericin formulated as a 0.25% hypericin ointment or gel.
Other Names:
|
|
Experimental: Cohort 2 - SGX302 Ointment (0.25 % Hypericin)
SGX302 (0.25 % hypericin) ointment will be applied to lesions and treated with visible light 24±6 hours later starting at 5 J/cm^2 with a faster escalation of light therapy up to 25 J/cm^2. Drug application/light session will be done twice a week (at least 2 calendar days apart) for 18 weeks. |
SGX302 is synthetic hypericin formulated as a 0.25% hypericin ointment or gel.
Other Names:
|
|
Experimental: Cohort 3 - SGX302 Gel (0.25 % Hypericin)
SGX302 (0.25 % hypericin) gel will be applied to lesions and treated with visible light 24±6 hours later starting at 5 J/cm^2 with a faster escalation of light therapy up to 40 J/cm^2. Drug application/light session will be done twice a week (at least 2 calendar days apart) for 18 weeks. |
SGX302 is synthetic hypericin formulated as a 0.25% hypericin ointment or gel.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of Patients That Achieve a 0 or 1 Score Using the 5-point Investigator's Global Assessment Scale
Time Frame: 18 weeks
|
The percentage of patients in each treatment group that achieve a 0 or 1 score (Clear or Almost Clear) evaluation using the 5-point Investigator's Global Assessment (IGA) scale. The 5-point IGA scale:
|
18 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
SkinDex-29 Score
Time Frame: Baseline, End of Treatment (Week 18)
|
The SkinDex-29 is a validated quality of life questionnaire that measures the effects of skin diseases on a person's life. It is a series of 30 questions assessing the participant's opinion of the impact of their disease on their life in the previous 4 weeks. Answers are scored from 1 (never), 2 (rarely), 3 (sometimes), 4 (often) to 5 (all the time) and are summed to get a total score. The minimum score possible is 30 and the maximum score possible is 150. A lower score means a better outcome. |
Baseline, End of Treatment (Week 18)
|
|
Dermatology Life Quality Index Score
Time Frame: Baseline, End of Treatment (Week 18)
|
The Dermatology Life Quality Index was developed as a general quality of life instrument to measure the impact of chronic skin disease on patients. The aim of the questionnaire is to measure how much the participant's skin problems affected their life over the past week. The questionnaire contains 10 questions with responses ranging from 0 (not at all), 1 (a little), 2 (a lot) to 3 (very much) that are summed to get a total score. The minimum score possible is 0 and the maximum score possible is 30. A lower score means a better outcome. |
Baseline, End of Treatment (Week 18)
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- HPN-PSR-01
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.